Robert A. Bellantone PhD

Dr. Robert A. Bellantone, Ph.D. is the President and Chief Scientific Officer of Physical Pharmaceutica, LLC. He also holds the designation of Professor Emeritus at Long Island University. Dr. Bellantone earned a B.S. in pharmacy and a Ph.D. in physics, and also completed all of the Ph.D. courses in pharmaceutics, all at the University of Connecticut. In 2016, Dr. Bellantone retired as a full professor from the College of Pharmacy at Long Island University, where he taught and performed research for nearly 20 years and served as a major research adviser to 29 Ph.D. graduates. He is the author or co-author of over 100 peer-reviewed research articles and presentations and the author of a book chapter on amorphous solids. He has presented his research numerous times at the U.S. Food and Drug Administration, on such topics as pulsatile microdialysis (PMD), in vitro release test methods for complex ophthalmic formulations such as emulsions, and nanoparticle dissolution.

Dr. Bellantone is an expert in formulation material science, in vitro release test methods, biopharmaceutics and pharmacokinetics, and computational modeling. He is also experienced in regulatory affairs and has developed and written bioequivalence sections for filed ANDAs. He has developed novel drug delivery technologies and numerous in vitro release test (IVRT) methods for the evaluation of complex dosage forms and has been awarded nine U.S. patents as the sole named inventor, including five patents for pulsatile microdialysis (PMD), which is the core technology for a number of IVRTs for complex products. He also consultants for the pharmaceutical industry, and has served as an expert witness and testified at trial in Federal Court in numerous pharmaceutical patent litigations in formulation science and pharmacokinetics.

Dr. Bellantone is currently developing in vitro release tests and models for data analysis for specialized applications such as ophthalmic emulsions, ophthalmic suspensions, and complex (liposomal and drug-protein) injectables. He is also developing an ocular PBPK (physiologically based pharmacokinetic) model that will interface with PMD-based IVRT data for ocular pharmacokinetic simulations and predictions.